Get the best in custom peptide synthesis from Mimotopes.

With fully customisable sequences, including adjustments to peptide length, a wide range of additional modifications, and options for the N and C termini, we can start building the ideal peptides for your research today.

As experts in custom peptide manufacturing, we can modify peptides to suit any purpose. They can be supplied individually or as part of a PepSet™Peptide Library. Modifications can be made at the terminal ends of the peptide or internally.

Cyclisation

An unrestrained peptide may be unstable and unreliable. Cyclisation constrains conformations to add stability and increase peptide function.

Here are some examples of the cyclised peptides we provide.

Biotinylation

Biotinylated peptides make ideal candidates for screening purposes. Biotinylation allows a peptide to be immobilised or detected, which is especially useful in a PepSet™ Peptide Library.

Conjugation

Conjugation is a versatile custom peptide modification with applications in antibody generation, affinity purification, and cell transport, to name a few.


It’s possible to produce an immunogen by conjugating a peptide to a carrier protein, couple peptides to gel for affinity purification, or build heterodimers to cross the cell membrane.

and many more

The list of peptide modifications goes on!

  • Stable isotope labeled peptides
  • FRET peptides
  • fluorescently labelled peptides
  • Branched peptides
  • Phosphorylation
  • Glycosylation
  • Methylation
  • Acetylation
  • Pegylation
  • Amidation
  • Succinylation
  • Carbamylation
  • Fatty acid capping
  • Photocleavable linkers

Contact us today for a peptide quote! 

Australia

☎ +61 3 9565 1111

✉ australia@mimotopes.com

North and South America 

☎ +1 651 603 0909

✉ useast@mimotopes.com
     uswest@mimotopes.com

asia

☎ +61 3 9565 1111

✉ asia@mimotopes.com

UK / Europe / Africa / Middle East

☎ +44 (0)151 556 0547

✉ europe@mimotopes.com

Go to article: Home | The power of patientsGo to article: Scandinavian Health Company InsightGo to article: Scandinavian Health Ltd.Go to article: In this issueGo to article: NSFGo to article: ContentsGo to article: CapsugelGo to article: Capsugel Company Insight Go to article: Christensella: the key to unlocking gut microbiome-based drug discovery?Go to article: Molnar Company InsightGo to article: Molnar-InstituteGo to article: A costly oversight: the ongoing impact of the valsartan recallGo to article: Novo Nordisk Company InsightGo to article: Novo NordiskGo to article: Where is the UK’s supply of Migraleve?Go to article: Dupont PharmaceuticalsGo to article: Discussing drug policy reform with psychedelics campaigner Amanda FeildingGo to article: LB Bohle Company Insight Go to article: LB BohleGo to article: Charting the life and times of the EMA as it leaves LondonGo to article: Komtur Pharmaceuticals Company InsightGo to article: Komtur PharmaceuticalsGo to article: CBD: the myth, the magic and the real deal drugsGo to article: CBDepot Company InsightGo to article: CBDepotGo to article: In the age of AMR, does a nationalised drug company make sense? The case for and againstGo to article: AtoZ-CRO Company InsightGo to article: AtoZ-CROGo to article: How do cancer cells communicate and can it help us catch them?Go to article: HOF SonderanlagenbauGo to article: HOF Sonderanlagenbau Company Insight Go to article: Buyers’ clubs: the first step toward universal UK access to Orkambi?Go to article: SterigenicsGo to article: Owen MumfordGo to article: Are we nearing the end of animal testing in pharma?Go to article: Zenatek Go to article: Barc Lab Go to article: A safer ride: the latest innovation in targeted cancer treatment Go to article: Abiogen PharmaGo to article: MimotopesGo to article: Next issue